Uveal Melanom

Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012;38:549–553. doi.org/10.1016/j.ctrv.2012.01.002

Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol Oncol Clin N Am. 2012;26:1170–1184. doi:10.1016/j.hoc.2012.08.004

Jager M.J., Shields C.L., Cebulla C.M., et al. Uveal melanoma. Nat. Rev. Dis. Primers. 2020;6:24. doi: 10.1038/s41572-020-0158-0.

Bronkhorst I.H.G., Jager M.J. Inflammation in uveal melanoma. Eye. 2013;27:217–223. doi: 10.1038/eye.2012.253.

Al-Jamal R.T., Cassoux N., Desjardins L., et al. The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group. Ophthalmology. 2016;123:898–907. doi: 10.1016/j.ophtha.2015.12.024.

Singh A.D., Turell M.E., Topham A.K. Uveal Melanoma: Trends in Incidence, Treatment, and Survival. Ophthalmology. 2011;118:1881–1885. doi: 10.1016/j.ophtha.2011.01.040

McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000–1007. doi: 10.1002/cncr.20866.

Virgili G., Gatta G., Ciccolallo L., et al. EUROCARE Working Group Incidence of Uveal Melanoma in Europe. Ophthalmology. 2007;114:2309–2315. doi: 10.1016/j.ophtha.2007.01.032

Hu DN, Yu GP, McCormick SA,et al. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612–617. doi: 10.1016/j.ajo.2005.05.034

Augsburger JJ, Schroeder RP, Territo C, et al. Clinical parameters predictive of enlargement of melanocytic choroidal lesions. Br J Ophthalmol 1989; 73:911. doi: 10.1136/bjo.73.11.911.

Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Expert Rev Ophthalmol 2007; 2:939.

Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997; 115:1537. doi: 10.1001/archopht.1997.01100160707007

Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009; 127:981. doi: 10.1001/archophthalmol.2009.151.

Bataille V, Sasieni P, Cuzick J, et al. Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer 1995; 60:622. doi: 10.1002/ijc.2910600509.

van Hees CL, de Boer A, Jager MJ, et al. Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol 1994; 103:202. doi: 10.1111/1523-1747.ep12392754.

Singh AD, De Potter P, Fijal BA, et al. Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology 1998; 105:195. doi: 10.1016/s0161-6420(98)92205-9.

Tucker MA, Shields JA, Hartge P, et al. Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med 1985; 313:789. doi: 10.1056/NEJM198509263131305.

Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 1990; 108:1274. doi: 10.1001/archopht.1990.01070110090031

Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 2005; 112:1599. doi: 10.1016/j.ophtha.2005.04.020.

Walpole S., Pritchard A.L., Cebulla C.M., et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J. Natl. Cancer Inst. 2018;110:1328–1341. doi: 10.1093/jnci/djy171.

Weis E., Shah C.P., Lajous M., et al. The association between host susceptibility factors and uveal melanoma: A meta-analysis. Arch. Ophthalmol. 2006;124:54–60. doi: 10.1001/archopht.124.1.54.

Eskelin S, Kivela T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol. 2002; 86: 333- 338. doi: 10.1136/bjo.86.3.333.

Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119(8):1582–1589. doi: 10.1016/j.ophtha.2012.01.048.

Grossniklaus HE, Syed N, Hogan RN, Lloyd WC 3rd, Folberg R. Inadvertent evisceration of eyes containing uveal melanoma. Arch Ophthalmol. 2009; 127: 141- 145. doi: 10.1001/archophthalmol.2008.543.

Freedman MI, Folk JC. Metastatic tumors to the eye and orbit. Patient survival and clinical characteristics. Arch Ophthalmol 1987; 105:1215. doi: 10.1001/archopht.1987.01060090073031.

Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study: COMS report no. 1. Arch Ophthalmol. 1990;108(9):1268–1273. doi: 10.1001/archopht.1990.01070110084030.

Shields, Carol L et al. “American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture.” Ophthalmology vol. 122,6 : 1180-1186. doi:10.1016/j.ophtha.2015.01.026

Diener West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enroll ment in the COMS trials for treatment of choroidal melanoma: Collaborative ocular melanoma study group report No. 26. Arch Ophthalmol 123: 1639 1643. doi: 10.1001/archopht.123.12.1639.

KrantzBA, Dave N, Komatsubara KM, et al.Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 11: 279 289, 2017. doi: 10.2147/OPTH.S89591.

Augsburger JJ, Gamel JW. Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 1990; 66:1596. doi:10.1002/1097-0142(19901001)66:7

Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101:1894. doi: 10.1001/archopht.1983.01040020896012.

Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119:1596. doi: 10.1016/j.ophtha.2012.02.017

Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 2007; 13:1466. doi: 10.1158/1078-0432.CCR-06-2401.

Petrausch U, Martus P, Tönnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008; 22:997. doi: 10.1038/sj.eye.6702779.

Harbour JW, Chen R. The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr 2013; 5. doi:10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618

Schuster R, Bechrakis NE, Stroux A, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology 2011; 80:57. doi: 10.1159/000328283.

Aaberg TM Jr, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol 2014; 8:2449. doi: 10.2147/OPTH.S70839

Gezgin G, Luk SJ, Cao J, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol 2017; 135:541. doi: 10.1001/jamaophthalmol.2017.0729.

Collaborative Ocular Melanoma Study Group.. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670. doi: 10.1001/archopht.119.5.670.

Lane AM, Egan KM, Kim IK,et al. Mortality after diagnosis of small melanocytic lesions of the choroid. Arch Ophthalmol 2010; 128:996. doi: 10.1001/archophthalmol.2010.166.et al.

Damato BE, Heimann H, Kalirai H, et al. Age, survival predictors, and metastatic death in patients with choroidal melanoma: Tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol 132: 605 613, 2014. doi: 10.1001/jamaophthalmol.2014.77.

Straatsma BR, Diener West M, Caldwell R, et al. Collaborative Ocular Melanoma Study Group: Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol 136: 47 54, 2003. doi: 10.1016/s0002-9394(02)02270-5.

Damato BE. Local resection of uveal melanoma. Dev Ophthalmol 2012; 49:66. doi: 10.1159/000328261

Adams KS, Abramson DH, Ellsworth RM, et al. Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol 1988; 72:494. doi: 10.1136/bjo.72.7.494.

Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990; 97:769. doi: 10.1016/s0161-6420(90)32512-5.

Augsburger JJ, Corrêa ZM, Freire J,et al. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998; 105:1670. doi: 10.1016/S0161-6420(98)99037-6

Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Expert Rev Ophthalmol 2007; 2:939. Doi:10:1586/17469899.2.6.939.

Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology 2011; 118: 402–407. doi: 10.1016/j.ophtha.2010.06.007.

Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology 2014; 121: 269–275. doi: 10.1016/j.ophtha.2013.08.039

Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002; 120: 1665–1671. doi: 10.1001/archopht.120.12.1665.

Sikuade MJ, Salvi S, Rundle PA, et al. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye (Lond) 2015; 29:1194. doi: 10.1038/eye.2015.109.

Dunavoelgyi R, Dieckmann K, Gleiss A, et al. Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2012; 83:121. doi: 10.1016/j.ijrobp.2011.06.1957

Krema H, Heydarian M, Beiki-Ardakani A, et al. A comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma. Br J Ophthalmol 2013; 97:327. doi: 10.1136/bjophthalmol-2012-302808.

Foulds WS and Damato BE: Low energy long exposure laser therapy in the management of choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 224: 26 31, 1986. doi:10.1007/BF02144128

Godfrey DG, Waldron RG, Capone A Jr. Transpupillary thermotherapy for small choroidal melanoma. Am J Ophthalmol 1999; 128:88. doi: 10.1016/s0002-9394(99)00063-x.

Harbour JW, Meredith TA, Thompson PA,et al. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology 2003; 110:2207. doi: 10.1016/S0161-6420(03)00858-3.

Young LH, Howard MA, Hu LK, et al. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996; 114:186. doi:10.1001/archopht.1996.01100130180013

Fabian ID, Stacey AW, Papastefanou V, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. Eye (Lond) 2017; 31:519. doi: 10.1038/eye.2017.22

Desjardins L, Dorval T, Lévy C, et al. Randomised study on adjuvant therapy by DTIC in choroidal melanoma. Ophtalmogie 1998; 12: 168–173

Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009; 116: 2206–2212. doi: 10.1016/j.ophtha.2009.04.044.

Richtig E, Langmann G, Schlemmer G, et al. Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma. Ophthalmologe 2006; 103: 506–511. doi: 10.1007/s00347-006-1350-7

Mallikarjuna K, Pushparaj V, Biswas J, et al. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 2007; 32: 281–290. doi: 10.1080/02713680601161220.

Surriga O, Rajasekhar VK, Ambrosini G, et al. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther 2013; 12: 2817–2826. doi: 10.1158/1535-7163.MCT-13-0499.

Valsecchi, Matias E et al. “Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls.” Ophthalmology vol. 125,2 (2018): 210-217.. doi: 10.1016/j.ophtha.2017.08.017

Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012; 18: 408–416. doi: 10.1158/1078-0432.CCR-11-0946

Diener West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal mela noma: the collaborative ocular melanoma study group report 23. J Clin Oncol 22: 2438 2444, 2004. doi: 10.1200/JCO.2004.08.194.

Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005; 89:1270. doi: 10.1136/bjo.2005.069823.

Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, et al. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 2013; 6:1230.

Kujala E, Mäkitie T and Kivelä T: Very long term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651 4659, 2003. doi: 10.1167/iovs.03-0538.

Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021; 385:1196. doi: 10.1056/NEJMoa2103485.

Sato T, Nathan PD, Hernandez-Aya LF, et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma. J Clin Oncol 2017; 35S:ASCO #9531.

Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res 2020; 26:5869. doi: 10.1158/1078-0432.CCR-20-1247.

Flaherty LE, Unger JM, Liu PY, et al. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568. doi: 10.1097/00000421-199812000-00008.

Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39:1115. doi: 10.1016/s0959-8049(03)00132-1

Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122:3344. doi: 10.1002/cncr.30258.

Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019; 119:168. doi: 10.1016/j.ejca.2019.07.010.

Tolcher AW, Reeves JA, McKean M, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. J Clin Oncol 2021; 39;15.

Chandran SS, Somerville RP, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 2017. doi: 10.1016/S1470-2045(17)30251-6.

Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012; 18:408. doi: 10.1158/1078-0432.CCR-11-0946.